Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 2/20 | 1.00 |
| ▸ | HSD17B2 | P37059 | 2/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 2/20 | 1.00 |
| ▸ | RELA | Q04206 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoliquiritigenin SCHEMBL29522737 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AMAPTHPGD | |
| Isoliquiritigenin SCHEMBL30383629 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AMAPTHPGD | |
| Isoliquiritigenin SCHEMBL161169 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AMAPTHPGD | |
| Isoliquiritigenin SCHEMBL161168 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AMAPTHPGD | |
| Isoliquiritigenin SCHEMBL10408923 | 1.00 | CYP3A4 (1.00) | CYP3A4MEN1KMT2AMAPTHPGD | |
| Isoliquiritigenin SCHEMBL25206430 | 0.98 | CYP3A4 (0.97) | CYP3A4MEN1KMT2AMAPTHPGD | |
| SCHEMBL25208375 | 0.98 | MEN1 (0.96) | CYP3A4MEN1KMT2AMAPTHPGD | |
| SCHEMBL25188827 | 0.92 | CYP3A4 (0.84) | CYP3A4MEN1KMT2AMAPTHPGD | |
| SCHEMBL28084572 | 0.92 | CYP3A4 (0.84) | CYP3A4MEN1KMT2AMAPTHPGD | |
| SCHEMBL23303982 | 0.90 | CYP3A4 (0.82) | CYP3A4MEN1KMT2AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680720-A1 | OPTIMIZED PRODUCTION OF BRANCH POINT COMPOUNDS AND DERIVATIVES USING ALTERNATIVE ISOPENTENYL DIPHOSPHATE-SUPPLYING PATHWAYS | EvodiaBio ApS (DK) | 2026-01-21 | — | — | EP | claimed |
| US-12529077-B2 | Production of geranyl diphosphate-derived compounds | Københavns Universitet (DK) | 2026-01-20 | — | — | US | claimed |
| EP-3972833-B1 | METHOD OF PLASTICIZING AND DENSIFYING HYDROPHILIC POLYMERIC BIOMATERIALS AND HYDROPHILIC POLYMERIC BIOMATERIALS | NEYSES BENEDIKT MATTHIAS (SE) | 2025-09-10 | — | — | EP | claimed |
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2024189183-A1 | OPTIMIZED PRODUCTION OF BRANCH POINT COMPOUNDS AND DERIVATIVES USING ALTERNATIVE ISOPENTENYL DIPHOSPHATE-SUPPLYING PATHWAYS | EVODIABIO APS (DK) | 2024-09-19 | — | — | WO | claimed |
| CN-117247601-A | Polyion liquid/boron nitride nanosheet composite flame retardant as well as preparation method and application thereof | 北京服装学院 | 2023-12-19 | — | — | CN | claimed |
| US-20230159960-A1 | Production Of Geranyl Diphosphate-Derived Compounds | KOBENHAVNS UNIVERSITET (DK) | 2023-05-25 | — | — | US | claimed |
| US-20260116986-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | IMMUNEDGE INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2026042045-A1 | INDOLICIDINE-CONTAINING COMPOSITIONS FOR PERSONAL CARE/HYGIENE APPLICATIONS | ITC LIMITED (IN) | 2026-02-26 | — | — | WO | disclosed |
| US-20250290034-A1 | METHOD FOR PRODUCING NAÏVE PLURIPOTENT STEM CELLS | KYOTO UNIVERSITY (JP) | 2025-09-18 | — | — | US | disclosed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4582534-A1 | METHOD FOR PRODUCING NAÏVE PLURIPOTENT STEM CELLS | Kyoto University (JP) | 2025-07-09 | — | — | EP | disclosed |
| CN-111229320-B | Metal organic framework composite material grafted with ionic liquid and preparation method and application thereof | 辽宁大学 | 2022-07-19 | — | — | CN | disclosed |
| US-20220184020-A1 | Polyphenols as Modulators of Platelet Function | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220119840-A1 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | GENERATION BIO CO. | 2022-04-21 | — | — | US | disclosed |
| CN-111624271-B | Liquid chromatography method for detecting corresponding substance of peony and licorice decoction, standard fingerprint spectrum and application | 厦门中药厂有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220064173-A1 | INHIBITORS OF NEK7 KINASE | HALIA THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| CN-110117326-B | Xanthohumol-related protein and application thereof in stabilizing product in xanthohumol synthesis pathway | 中国科学院遗传与发育生物学研究所 | 2022-03-01 | — | — | CN | disclosed |
| CN-110117327-B | Xanthohumol-related protein and application thereof in preparation of product in xanthohumol synthesis pathway | 中国科学院遗传与发育生物学研究所 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12529077-B2 | Production of geranyl diphosphate-derived compounds | GGPS1, OGA, GBA3 | CYP3A4 224/4885MEN1 4421/4885KMT2A 3786/4885 |
| US-20220119840-A1 | CLOSED-ENDED DNA (CEDNA) AND USE IN METHODS OF REDUCING GENE OR NUCLEIC ACID THERAPY RELATED IMMUNE RESPONSE | STING1, DCLRE1B, DCLRE1A | CYP3A4 4882/4885MEN1 3970/4885KMT2A 1183/4885 |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | CYP3A4 1976/4885MEN1 361/4885KMT2A 2945/4885 |
| US-20260116986-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, STAT5A, JAK2 | CYP3A4 4330/4885MEN1 3558/4885KMT2A 1468/4885 |
| US-20220064173-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | CYP3A4 2521/4885MEN1 1766/4885KMT2A 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.